Tag: nasdaq:alxn

January 30, 2020

Alexion Reports Fourth Quarter and Full Year 2019 Results

Alexion Pharmaceuticals announced its financial results for the fourth quarter and its full fiscal 2019 year.
January 14, 2020

Alexion Confirms Planned Phase 3 Study of ALS Treatment

Alexion announced that is plans to start a Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).
December 4, 2019

5 Top NASDAQ Pharma Stocks of 2019

2019 is at an end, which means it's time to reflect on the top-performing NASDAQ pharma stocks year-to-date.
March 26, 2019

7 Potential Blockbuster Drugs Investors Should Watch for in 2019

A report by Cortellis says that seven drugs entering the market in 2019 are projected to reach blockbuster status by...
September 24, 2018

Alexion Announces Successful Phase 3 PREVENT Study of Soliris (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder

Alexion Pharmaceuticals (NASDAQ:ALXN) today announced positive topline results from the Phase 3 PREVENT study of Soliris (eculizumab) in patients with anti-aquaporin-4 (AQP4)...
June 28, 2018

Alexion Submits Application for Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria in the EU

Alexion Pharmaceuticals (NASDAQ:ALXN) announced the submission of a Marketing Authorization Application to the European Medicines Agency (EMA) for ALXN1210, the...